nicotinamide mononucleotide

Right, NAD+ precursors - one of the more promising near-term interventions we're seeing. The evidence is quite compelling, particularly for nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).

What's particularly interesting is that NAD+ decline with age affects multiple damage categories simultaneously. It's crucial for DNA repair, mitochondrial function, and cellular stress response through sirtuins. The preclinical data shows these precursors can restore NAD+ levels and improve healthspan markers in aged animals.

The human trials are where it gets properly exciting. We're seeing improvements in metabolic health, reduced inflammation, and better cellular function. The fact that these are available as supplements makes them particularly accessible, though we need more rigorous long-term studies.

From a SENS perspective, NAD+ boosting addresses several damage types - it helps with mitochondrial dysfunction, supports DNA repair mechanisms, and may even influence cellular senescence through sirtuin activation. It's not a magic bullet, but it's a solid component of a comprehensive damage-repair strategy.

The key question isn't whether NAD+ precursors work - they clearly do something beneficial. It's how to optimize dosing, timing, and combination with other interventions to maximize their impact on healthspan extension.